Scientists Pin Parkinson's Spread on 2 Cell-Surface Proteins, Opening Path to Disease-Modifying Drugs
Updated
Updated · Newsweek · Jul 13
Scientists Pin Parkinson's Spread on 2 Cell-Surface Proteins, Opening Path to Disease-Modifying Drugs
3 articles · Updated · Newsweek · Jul 13
Summary
Two nerve-cell surface proteins—mGluR4 and NPDC1—appear to act as the entry route for misfolded alpha-synuclein, giving researchers a clearer mechanism for how Parkinson's spreads through the brain.
Yale scientists identified the pair after screening thousands of cell-surface proteins and found the proteins work together as a receptor complex that helps toxic alpha-synuclein bind to and enter healthy neurons.
Mouse and lab experiments showed that blocking or removing both proteins sharply reduced Parkinson's-like damage, with dopamine-producing neurons largely protected from degeneration after alpha-synuclein exposure.
mGluR4 may offer the faster treatment path because drugs against it are considered plausible and some have already entered trials, though not yet for blocking synuclein.
The finding points toward therapies that could slow, halt or potentially reverse disease progression rather than only ease symptoms for the roughly 1.1 million Americans living with Parkinson's.
Blocking the protein 'doorway' for Parkinson's is a new hope, but could it inadvertently harm healthy brain function?
With new tests detecting Parkinson's early, can this breakthrough finally provide a treatment that stops the disease in its tracks?
Late 2025 Discovery Identifies mGluR4-NPDC1 Complex as Key to Parkinson’s Spread and Promising Therapeutic Target
Overview
In late 2025, researchers from Yale School of Medicine made a major breakthrough in understanding how Parkinson's disease progresses. Their study, published in Nature Communications, revealed that misfolded alpha-synuclein proteins—central to Parkinson's—spread from one neuron to another, driving the disease forward. The team discovered a key 'gatekeeper' complex on neuron surfaces, made of mGluR4 and NPDC1 proteins, which allows these harmful proteins to enter healthy brain cells. This finding uncovers the fundamental mechanism behind Parkinson's progression and offers a promising new target for developing treatments that could slow or stop the disease.